anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

212,581-212,640 of 319,975

filter-aware
08
Eos Energy | Results Presentation Deck | 13 slidesEos Energy | Results Presentation Deck | 13 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
The slide uses a funnel-like progression from lead generation to backlog.Eos Energy | Results Presentation Deck | 13 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
The slide uses a process flow framework to explain revenue recognition and cash collection timing.Eos Energy | Results Presentation Deck | 13 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
11
Eos Energy | Results Presentation Deck | 13 slidesEos Energy | Results Presentation Deck | 13 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
12
The slide uses a waterfall-style comparison for Revenue and COGS to emphasize year-over-year changes.Eos Energy | Results Presentation Deck | 13 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
13
The slide uses a structured list format to present three distinct performance categories.Eos Energy | Results Presentation Deck | 13 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Action1 hit
01
Slide 1
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
02
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram to centralize the company brand around key investment pillars.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
04
The slide uses a Gantt-style visualization for clinical trial stages.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
05
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
06
Includes footnote regarding currency exchange rate for the option exercise payment.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
07
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
08
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
09
Includes a diagram illustrating cytokine-receptor binding and downstream signaling.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
10
The slide uses a visual comparison to frame the problem of 'too narrow' vs 'too broad' inhibition.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
13
The slide illustrates a structural biology approach to drug design, focusing on helix-receptor interactions and sequence engineering.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
14
The slide uses a combination of biological process diagrams and a bar chart to demonstrate selective inhibition.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
15
The slide uses a visual comparison framework to illustrate the mechanism of action and therapeutic benefits.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
16
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
17
The slide uses a structured layout to compare four distinct market segments (Cutaneous T cell Lymphoma, Alopecia Areata, Vitiligo, Atopic Dermatitis) with specific patient counts and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
18
The slide uses a four-column structure to explain the target, the molecule type, preclinical results, and clinical results.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
19
Western blot data visualization comparing pathway activation (pSTAT, pERK, pPI3K) under different treatment conditions.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
20
Includes comparative data against Mogamulizumab (MAVORIC trial) and visual evidence of skin improvement.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
21
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
22
The slide uses a circular process diagram to show the feedback loop of immune cell activation and hair follicle damage.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes photographic evidence of hair regrowth over 21 days and a bar chart showing fold reduction of NKG2D marker.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
24
The slide compares two different drugs (baricitinib and deuruxolitinib) using their respective clinical trial data (BRAVE AA1 and THRIVE AA1).Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a blackbox warning text block as a competitive/safety barrier context.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide outlines a clinical trial methodology and the strategic positioning of the drug candidate.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
28
Uses a contrast-based framing (750k patients vs 0 drugs) to establish market opportunity.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
The slide uses a four-column structure to explain the biological rationale, molecular nature, mechanism of action, and clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a heatmap showing gene expression profiles under different cytokine conditions.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a circular process diagram to show the mechanism of action and a bar chart to show efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
32
The slide uses a process-like flow to highlight the specific mechanism of action (IL-15/IL-21) compared to other approaches.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
33
The slide outlines a sequential clinical trial process.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Why Now1 hit
34
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
35
The slide combines individual team member bios with a collective logo grid of past affiliations.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Team1 hit
36
The slide uses a Gantt-style timeline to show the duration of IP protection for various therapeutic assets.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Team1 hit
37
Includes a disclaimer regarding the Form 10-Q and a footnote about debt facility prepayment.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
38
The slide uses a table-like structure to present clinical trial milestones and financial runway.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
39
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
01
Slide 1
The slide uses a high-quality stock photo to evoke an emotional connection to the company's mission.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
02
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram to connect the company name to three core pillars: leadership, portfolio, and financials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
04
SAB stands for Scientific Advisory Board.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
05
The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a Gantt-style visualization for clinical trial stages.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The chart uses a stacked bar approach to represent US and European patient counts per clinical program.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The kinome tree visualization (KINOMEscan) is a standard industry tool for demonstrating kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide combines a biological pathway diagram (mechanism of action) with a clinical trial summary table.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit